Quantification of the oxidative damage biomarker 2,3-dinor-8-isoprostaglandin-F2α in human urine using liquid chromatography-tandem mass spectrometry

Analytical Biochemistry

Volumn 399, Issue 2, 2010, Pages 302-304

  Zhang, Haoyue ^a   Il'yasova, Dora ^a   Sztaray, Judit ^a   Young, Sarah P ^a   Wang, Frances ^a   Millington, David S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; ELECTROSPRAY IONIZATION; MASS SPECTROMETRY; METABOLITES; NEGATIVE IONS; PHASE SEPARATION;

ION ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LOWER LIMIT OF QUANTIFICATIONS; OXIDATIVE DAMAGE; SOLID-PHASE EXTRACTION; TANDEM MASS SPECTROMETRIC; ULTRAPERFORMANCE LIQUID CHROMATOGRAPHY; URINARY METABOLITES;

LIQUID CHROMATOGRAPHY;

2,3 DINOR 8 ISOPROSTAGLANDIN F2ALPHA; 8 ISOPROSTAGLANDIN F2 ALPHA; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CONTROLLED STUDY; LIQUID CHROMATOGRAPHY; METABOLITE; NEGATIVE ION ELECTROSPRAY; PRIORITY JOURNAL; PURIFICATION; QUANTITATIVE ANALYSIS; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TIME; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS;

EID: 77049123659     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2009.12.024     Document Type: Article

References (18)

1. Halliwell B., and Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. Br. J. Pharmacol. 142 (2004) 231-255
2. Rokach J., Khanapure S.P., Hwang S.W., Adiyaman M., Lawson J.A., and FitzGerald G.A. The isoprostanes: a perspective. Prostaglandins 54 (1997) 823-851
3. Schwedhelm E., and Boger R.H. Application of gas chromatography-mass spectrometry for analysis of isoprostanes: their role in cardiovascular disease. Clin. Chem. Lab. Med. 41 (2003) 1552-1561
4. Greco A., Minghetti L., and Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem. Res. 25 (2000) 1357-1364
5. Devaraj S., Hirany S.V., Burk R.F., and Jialal I. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin. Chem. 47 (2001) 1974-1979
6. Pratico D., Iuliano L., Amerio G., Tang L.X., Rokach J., Sabatino G., and Violi F. Down's syndrome is associated with increased 8,12-iso-iPF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann. Neurol. 48 (2000) 795-798
7. Morrow J.D., and Roberts L.J. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am. J. Respir. Crit. Care Med. 166 (2002) S25-S30
8. Morrow J.D., Frei B., Longmire A.W., Gaziano J.M., Lynch S.M., Shyr Y., Strauss W.E., Oates J.A., and Roberts II L.J. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med. 332 (1995) 1198-1203
9. Bachi A., Zuccato E., Baraldi M., Fanelli R., and Chiabrando C. Measurement of urinary 8-Epi-prostaglandin F2alpha, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry. Basal levels in smokers and nonsmokers. Free Radic. Biol. Med. 20 (1996) 619-624
10. Il'yasova D., Morrow J.D., Ivanova A., and Wagenknecht L.E. Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane. Ann. Epidemiol. 14 (2004) 793-797
11. Nourooz-Zadeh J., Cooper M.B., Ziegler D., and Betteridge D.J. Urinary 8-epi-PGF2alpha and its endogenous beta-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress. Biochem. Biophys. Res. Commun. 330 (2005) 731-736
12. Yan W., Byrd G.D., and Ogden M.W. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J. Lipid Res. 48 (2007) 1607-1617
13. Liang Y., Wei P., Duke R.W., Reaven P.D., Harman S.M., Cutler R.G., and Heward C.B. Quantification of 8-iso-prostaglandin-F(2alpha) and 2,3-dinor-8-iso-prostaglandin-F(2alpha) in human urine using liquid chromatography-tandem mass spectrometry. Free Radic. Biol. Med. 34 (2003) 409-418
14. Masoodi M., and Nicolaou A. Lipidomic analysis of 27 prostanoids and isoprostanes by liquid chromatography/electrospray tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20 (2006) 3023-3039
15. Davies S.S., Zackert W., Luo Y., Cunningham C.C., Frisard M., and Roberts II L.J. Quantification of dinor, dihydro metabolites of F2-isoprostanes in urine by liquid chromatography/tandem mass spectrometry. Anal. Biochem. 348 (2006) 185-191
16. Haschke M., Zhang Y.L., Kahle C., Klawitter J., Korecka M., Shaw L.M., and Christians U. HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. Clin. Chem. 53 (2007) 489-497
17. Waugh R.J., Morrow J.D., Roberts II L.J., and Murphy R.C. Identification and relative quantitation of F2-isoprostane regioisomers formed in vivo in the rat. Free Radic. Biol. Med. 23 (1997) 943-954
18. Block G., Dietrich M., Norkus E., Jensen C., Benowitz N.L., Morrow J.D., Hudes M., and Packer L. Intraindividual variability of plasma antioxidants, markers of oxidative stress, C-reactive protein, cotinine, and other biomarkers. Epidemiology 17 (2006) 404-412